🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07246811
Starting soon Not applicable

Rehabilitation Exercise Intervention for Rheumatoid Arthritis Patients Using Artificial Intelligence-Based Exercise Prescription System

NCT07246811 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Not applicable
Started
2025-11-30
Last updated
2025-11-24

Condition(s) studied

Rheumatoid Arthritis (RA)

Investigational drug(s) / intervention(s)

AI Exercise Prescriptioneducation and basic joint mobility exercisespaper-based exercise prescription

AI Exercise Prescription: Uses "Yidong Health AI Exercise Prescription System" delivered via WeChat mini-program, providing personalized exercise prescriptions (three sets: A/B/C) with AI Q\&A module. Physicians adjust prescriptions weekly based on patient feedback.

education and basic joint mobility exercises: Receives standardized RA disease management education and basic joint mobility exercises provided by rheumatology nurses.

paper-based exercise prescription: Receives paper-based exercise prescription developed by rehabilitation therapists, including warm-up, formal training (bridging, modified bird-dog exercise, etc.) and cool-down stretching.

Study summary

This is a single-center, randomized, parallel-controlled trial evaluating the efficacy and safety of an artificial intelligence-based exercise prescription system for rehabilitation in rheumatoid arthritis (RA) patients. A total of 147 patients with low-to-moderate disease activity will be randomly assigned to three groups: AI exercise prescription group (personalized AI system guidance), paper exercise prescription group (traditional paper guidance), and routine care group. The intervention will last for 6 weeks with 6-month follow-up assessments evaluating joint function, pain, and quality of life indicators.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years Meets 2010 ACR/EULAR classification criteria for RA Low-to-moderate disease activity (assessed by rheumatologist) Knee joint involvement Willing and able to provide informed consent Exclusion Criteria: * Existing joint ankylosis (fibrous or bony) Acute flare or extra-articular soft tissue lesions Comorbid with other rheumatic diseases (e.g., SLE, Sjögren's syndrome) Severe hepatic or renal impairment Knee joint VAS pain score \>4 (0-10 scale) Psychiatric disorders

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Rehabilitation Medicine, Peking University People's Hospital Beijing Beijing Municipality

More Peking University Third Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07246811 on ClinicalTrials.gov ↗ ← All trials in China